About the Company

Heat Biologics (NasdaqCM: HTBX) is a biotechnology company developing allogeneic, off the-shelf immunotherapies for oncology using its proprietary ImPACT® technology. The Company’s approach is to induce pan-antigen expression and specific activation of cytotoxic T-cells to target and destroy cancer cells. Phase II trials are underway targeting the treatment of third or fourth-line non-small cell lung cancer (NSCLC) and non-muscle invasive bladder cancer (NMIBC).

Source: LifeSci Capital, LLC research report

Research analyst certification and important disclosures can be found in the full research report. To access the full research report, please click on the link below.

Recent Research